{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"37.4","upperLimit":"60.2","value":"48.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"}],"units":"Participants"}],"description":"Durable CR was defined as overall response that meets blood, bone marrow and imaging criteria for CR, followed by a \\>180 day duration of HR. CR requires all of the following to be present: No evidence of leukemic cells in peripheral blood and/or by routine H/E staining of bone marrow; Resolution of any hepatomegaly, splenomegaly, and abnormal (\\>= 2 cm minimum length) lymphadenopathy by CT or MRI (maximum diameter of spleen should be either \\< 17 cm or have decreased by \\>25% from its baseline.); HR requires normal complete blood count (CBC) as exhibited by: Neutrophils \\>= 1.5 x 10\\^9/L, Platelets \\>= 100 x 10\\^9/L, and hemoglobin \\>= 11.0 g/dL without transfusions or growth factors for at least 4 weeks.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received intravenous infusion of moxetumomab pasudotox 40 µg/kg on Days 1, 3, and 5 of each 28-day cycle for up to 6 cycles, until documentation of complete response, progressive disease, initiation of alternate therapy, or unacceptable toxicity.","id":"OG000","title":"Moxetumomab Pasudotox 40 µg/kg"}],"paramType":"NUMBER","populationDescription":"The ITT population included participants who entered into the study and treated with moxetumomab pasudotox.","reportingStatus":"POSTED","timeFrame":"Full disease assessment (CBC, bone marrow and imaging) at end of treatment (EOT; up to 24 weeks) and post EOT Day 181; CBC monthly for 6 months post EOT, every 3 months post Day 181 for first 2 years and every 6 months thereafter (approximately 6 years)","title":"Percentage of Participants With Durable CR by Investigator's Assessment","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}